FORMULATION AND DEVELOPMENT OF SUSTAINED RELEASE MATRIX TABLETS OF LORNOXICAM

  • Rahul Pagar K.B.H.S.S. T'S Institute Of Pharmacy, Malegaon, Nashik, 423105.
  • D M PATIL KBHSS Trust’s Institute of Pharmacy, Malegaon, Nashik, MS.
  • P A PAWAR KBHSS Trust’s Institute of Pharmacy, Malegaon, Nashik, MS.
  • R S GHULE KBHSS Trust’s Institute of Pharmacy, Malegaon, Nashik, MS, India
  • V A BAIRAGI KBHSS Trust’s Institute of Pharmacy, Malegaon, Nashik, MS, India

Abstract

Lornoxicam is a NSAID having oxicam class mainly prescribed in the treatment of osteoarthritis and rheumatoid arthritis. NSAID have the potential to relieve the pain and inflammation without the immunosuppressive and metabolic side effects associated with corticosteroids. Generally the classification of NSAID is applied to drugs that inhibit one or more steps in the metabolism of Arachidonic Acid (AA). In general, NSAID do not inhibit lipoxygenase formation or the formation of other inflammatory mediators. Due to its more biological half-life i.e. 3-5 hrs. in India, the dosage form is available in 8-16 mg, it can be increased upto 24 mg/day if necessary. The main objectives of present investigation are to confirm the drug by various analytical techniques, to study the drug excipients compatibility, to avoid the dose as well as the frequency of the dosage form and to perform the stability. The tablet can be developed with the combination of HPMC K 100M and Ethyl Cellulose as a matrix former. Lornoxicam is NSAID that has numerous functions in the body. It can be absorbed rapidly and completely from gastrointestinal track after the oral administration. Absolute bioavailability of Lornoxicam is 90-100%. No first pass effect is observed. It is found in the plasma in the unchanged form and as its hydroxylated metabolite. The hydroxylated metabolite exhibits no pharmacological activity. CYP2C3 has been shown to be the primary enzyme responsible for the biotransformation of Lornoxicam. Approximately 2/3 part of Lornoxicam is eliminated via the liver and 1/3 via the kidneys as inactive substance. Lornoxicam inhibits the production of prostaglandins by inhibiting the action of cyclooxygenase, which regulates the conversion of Arachidonic Acid to Prostaglandins. Lornoxicam mainly prescribed in the treatment of osteoarthritis and rheumatoid arthritis, and also in the management of ankylosing spondylitis, acute sciatica and low back pain.

Keywords: Lornoxicam, Sustained release, matrix.


Downloads

Download data is not yet available.

Author Biographies

D M PATIL, KBHSS Trust’s Institute of Pharmacy, Malegaon, Nashik, MS.

Associated professor, KBHSS Trust’s Institute of Pharmacy, Malegaon, Nashik, MS, India

 

P A PAWAR, KBHSS Trust’s Institute of Pharmacy, Malegaon, Nashik, MS.

KBHSS Trust’s Institute of Pharmacy, Malegaon, Nashik, MS.

R S GHULE, KBHSS Trust’s Institute of Pharmacy, Malegaon, Nashik, MS, India
KBHSS Trust’s Institute of Pharmacy, Malegaon, Nashik, MS, India
V A BAIRAGI, KBHSS Trust’s Institute of Pharmacy, Malegaon, Nashik, MS, India
KBHSS Trust’s Institute of Pharmacy, Malegaon, Nashik, MS, India

References

1. Gudsoorkar VR, Rambhau D. “Influence variable of process one standard drug release from disintegrating sustained release Ibuprofen beads” Eastern Pharmacist,1997; 40(2):111-113.
2. Siddique S, Bose A, Khanam, J. “Modulation of drug (metoprolol succinate) release by inclusion of hydrophobic polymer in hydrophilic matrix.”Drug Dev Ind Pharm, 2011; 37(9):1016-1025.
3. Deore RK, Kavitha K, Tamizhmani TG. “Preparation and evaluation of sustained release matrix tablets of tramadol hydrochloride using glyceryl palmitostearate.”Trop J Pharm Res, 2010; 9(3):275-281.
4. Patel K., Vyas J., Upadhyay U. Formulation and evaluation of sustained release matrix tablets of nateglinide. Journal of Drug Delivery and Therapeutics, 2015; 5(5):19-25. doi:10.22270/jddt.v5i5.1130
5. Hamdani J, Moes AJ, Amighi K. “Development and evaluation of prolonged release pellets obtained by melt pelletization process.”Int J Pharm,2002; 245:167-177.
6. Jannin V, Cuppok Y. “Hot-melt coating with lipid excipient.”Int J Pharm, 2013; 457:480-487.
7. Dwivedi C., Rao S., Roy A., Saraf S., Kulsum U., Verma N., Pradhan D. Formulation and characterization of metformin hydrochloride sustained release matrix tablet containing Cassia tora mucilage. Journal of Drug Delivery and Therapeutics, 2017; 7(6):66-75. doi:10.22270/jddt.v7i6.1520
8. Momin S., Khan S., Ghadage D., Yadav A., Wagh A. Formulation and evaluation of bilayer tablets of propranolol hydrochloride. Journal of Drug Delivery and Therapeutics, 2017; 7(2):50-57. doi:10.22270/jddt.v7i2.1399
9. Sahoo C., Rao S., Sudhakar M. Formulation and evaluation of controlled porosity osmotic pump tablets for zidovudine and lamivudine combination using fructose as osmogen. Journal of Drug Delivery and Therapeutics, 2017; 7(4):41-50. doi:10.22270/jddt.v7i4.1465
10. Lloanusi NO, Schwartz JB. “The effect of wax on compaction of microcrystalline cellulose beads made by extrusion and spheronization.”Drug Dev Ind Pharm, 1998; 24:37-44.
11. Vinchurkar K., Mane S., Balekar N., Jain D. Formulation and evaluation of tablets containing artemether microspheres and lumefantrine. Journal of Drug Delivery and Therapeutics, 2017; 7(7):4-7. doi:10.22270/jddt.v7i7.1569
12. Sharma A., Sharma P., Darwhekar G. Formulation and evaluation of bilayer tablet of metronidazole and dicyclomine hydrochloride for treatment of irritable bowel disease. Journal of Drug Delivery and Therapeutics, 2017; 7(7):56-58. doi:10.22270/jddt.v7i7.1586
13. Julia A. Balfour, Andrew Fitton, Lee B. Barradell, Lornoxicam: A Review of its Pharmacology and Therapeutic Potential in the Management of Painful and Inflammatory Conditions, 1916; 51(4):639-657.
14. Indian Pharmacopoeia, Government of India, Ministry of health and family welfare, volume 1, published by The Indian Pharmacopoeia Comission, Gaziabad, 2014: 190.
15. The Merck Index, an encyclopedia of chemicals, drugs and biological, Fourteenth edition, published by Merck Research Laboratories: 5584.
16. Kumar GP, Battu G, Lova R, Kotha NS, Preparation and evaluation of sustained release matrix tablets of Lornoxicam using tamarind seed polysaccharide, Int. J. Pharm. Res. Dev, 2011; 2(12):89-98.
17. Reddy KR, Once daily sustained release matrix tablets of Nicorandil: Formulation and in-vitro evaluation. PharmSciTech, 2003, 4(4): E 61.
18. Yassin EI- said Hamza, Mona Hassan Aburahma, Design and in-vitro evaluation of novel sustained release matrix tablets for Lornoxicam based on the combination of hydrophilic matrix formers and basic pH- modifiers, Pharmaceutical Development and Technology, 2009; 15:139-153.
19. Garg A, Gupta MM, Taste masking and formulation development & evaluation of mouth dissolving tablets of levocetrizine dihydrochloride, Journal of Drug Delivery and Therapeutics; 2013; 3(3):123-130
Statistics
244 Views | 475 Downloads
How to Cite
1.
Pagar R, PATIL D, PAWAR P, GHULE R, BAIRAGI V. FORMULATION AND DEVELOPMENT OF SUSTAINED RELEASE MATRIX TABLETS OF LORNOXICAM. JDDT [Internet]. 14Mar.2018 [cited 31Oct.2020];8(2):102-6. Available from: http://www.jddtonline.info/index.php/jddt/article/view/1693